16:35 EDT Metagenomi (MGX) sees cash, equivalents supporting operations into 2027
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Metagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna Collaboration
- Metagenomi, Inc. Reports 2024 Financial Results and Pipeline Progress